| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NOTCH1 |
| Uniprot No | P46531 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2428-2555aa |
| 氨基酸序列 | HLGRSFLSGEPSQADVQPLGPSSLAVHTILPQESPALPTSLPSSLVPPVTAAQFLTPPSQHSYSSPVDNTPSHQLQVPEHPFLTPSPESPDQWSSSSPHSNVSDWSEGVSSPPTSMQSQIARIPEAFK |
| 预测分子量 | 48.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NOTCH1重组蛋白的3-4篇参考文献及其摘要概括：
---
1. **《Structural and functional analysis of the NOTCH1 EGF-like domains by recombinant expression》**
*Shimizu et al.*
该研究通过重组表达技术解析了NOTCH1胞外EGF样结构域的结构，揭示其与配体(如Delta/Jagged)结合的分子机制，为理解Notch信号传导的调控提供结构基础。
2. **《NOTCH1 mutations in human cancer: Mechanistic insights and therapeutic implications》**
*Aster et al.*
综述了NOTCH1在多种癌症(如T细胞白血病、实体瘤)中的突变谱，通过重组蛋白实验验证突变对Notch信号活化的影响，并探讨靶向治疗策略。
3. **《Antibody-based targeting of NOTCH1 recombinant extracellular domain inhibits tumor growth》**
*Wu et al.*
开发靶向NOTCH1重组胞外结构域的单克隆抗体，体外和体内实验表明其可阻断配体结合，抑制Notch信号通路，减缓肿瘤细胞增殖。
4. **《Negative regulatory regions of NOTCH1: Recombinant studies on O-glycosylation and ligand interaction》**
*Chillakuri et al.*
利用重组蛋白技术研究NOTCH1负调控区(NRR)的O-糖基化修饰及其对配体结合和信号激活的抑制作用，揭示其维持Notch受体失活状态的结构基础。
---
以上文献覆盖NOTCH1重组蛋白的结构解析、功能机制、疾病关联及治疗应用，可供快速参考。如需具体细节，建议通过PubMed或学术数据库检索完整原文。
**Background of NOTCH1 Recombinant Protein**
The NOTCH1 receptor is a critical component of the evolutionarily conserved Notch signaling pathway, which regulates cell fate determination, proliferation, differentiation, and apoptosis during development and tissue homeostasis. Structurally, NOTCH1 is a single-pass transmembrane protein composed of an extracellular domain (ECD) containing multiple epidermal growth factor (EGF)-like repeats, a transmembrane (TM) domain, and an intracellular domain (NICD). Signaling is initiated upon ligand binding (e.g., Delta-like or Jagged proteins), triggering proteolytic cleavage events that release NICD into the nucleus to modulate gene expression.
Recombinant NOTCH1 proteins are engineered in vitro to study the molecular mechanisms of Notch signaling or develop therapeutic interventions. These proteins often include soluble forms of the ECD for ligand interaction studies, truncated variants to analyze specific domains, or modified versions (e.g., tagged or mutated) for structural and functional characterization. Notably, dysregulated NOTCH1 signaling is implicated in cancers (e.g., T-cell acute lymphoblastic leukemia), cardiovascular disorders, and developmental syndromes, making recombinant NOTCH1 a valuable tool for drug screening and mechanistic research.
Production typically involves expression systems like mammalian cells (HEK293 or CHO) or insect cells to ensure proper post-translational modifications, such as glycosylation, which is critical for ligand binding. Recombinant NOTCH1 proteins are widely utilized in ligand-receptor binding assays, crystallography, and inhibitor screening, aiding the development of targeted therapies against Notch-related pathologies.
×
